213 related articles for article (PubMed ID: 15880129)
1. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
Staber PB; Holub R; Linkesch W; Schmidt H; Neumeister P
Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
[TBL] [Abstract][Full Text] [Related]
4. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
Gerds A; Fox-Geiman M; Dawravoo K; Rodriguez T; Toor A; Smith S; Kiley K; Fletcher-Gonzalez D; Hicks C; Stiff P
Biol Blood Marrow Transplant; 2010 May; 16(5):678-85. PubMed ID: 20045479
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Rifkin R; Spitzer G; Orloff G; Mandanas R; McGaughey D; Zhan F; Boehm KA; Asmar L; Beveridge R
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):186-91. PubMed ID: 20511163
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
8. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
Vanstraelen G; Frère P; Ngirabacu MC; Willems E; Fillet G; Beguin Y
Exp Hematol; 2006 Mar; 34(3):382-8. PubMed ID: 16543072
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
Samaras P; Blickenstorfer M; Siciliano RD; Haile SR; Buset EM; Petrausch U; Mischo A; Honegger H; Schanz U; Stussi G; Stahel RA; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens.
Nosari A; Cairoli R; Ciapanna D; Gargantini L; Intropido L; Baraté C; Scarpati B; Santoleri L; Nador G; Pezzetti L; Morra E
Bone Marrow Transplant; 2006 Sep; 38(6):413-6. PubMed ID: 16878144
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.
Mathew S; Adel N; Rice RD; Panageas K; Duck ET; Comenzo RL; Kewalramani T; Nimer SD
Bone Marrow Transplant; 2010 Oct; 45(10):1522-7. PubMed ID: 20062102
[TBL] [Abstract][Full Text] [Related]
15. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients.
Isidori A; Tani M; Bonifazi F; Zinzani P; Curti A; Motta MR; Rizzi S; Giudice V; Farese O; Rovito M; Alinari L; Conte R; Baccarani M; Lemoli RM
Haematologica; 2005 Feb; 90(2):225-31. PubMed ID: 15710576
[TBL] [Abstract][Full Text] [Related]
17. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
Faber E; Pytlík R; Slabý J; Zapletalová J; Kozák T; Raida L; Papajík T; Zikesová E; Maresová I; Hamouzová M; Indrák K; Trnený M
Eur J Haematol; 2006 Dec; 77(6):493-500. PubMed ID: 17042769
[TBL] [Abstract][Full Text] [Related]
18. The role of pegfilgrastim in mobilization of hematopoietic stem cells.
Kroschinsky F; Hölig K; Ehninger G
Transfus Apher Sci; 2008 Jun; 38(3):237-44. PubMed ID: 18490197
[TBL] [Abstract][Full Text] [Related]
19. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
20. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
